News - Gilead Sciences

Filter

Current filters:

Gilead Sciences

Popular Filters

55 to 79 of 123 results

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26-03-2013

US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

AHF demands FDA reversal on use of Gilead's HIV prevention pill for women

06-03-2013

Citing another failed clinical trial in women of the use of Gilead Sciences' (Nasdaq: GILD) AIDS drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationResearchTruvada

Gilead and Teva settle Viread patent litigation

20-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Gilead rises as sofosbuvir meets endpoints in Ph III hepatitis C study

20-02-2013

US AID/HIV drug giant Gilead Sciences (Nasdaq: GILD) saw its shares rise 2.5% to $42.60 in morning trading…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Gilead 4th-qtr sales and earnings beat forecasts, but slammed for "greed" by AHF

05-02-2013

USA-based Gilead Sciences (Nasdaq: GILD), the leading maker of HIV/AIDS drugs, yesterday posted financial…

Anti-viralsBiotechnologyFinancialGilead SciencesPricing

Positive results from two Ph III Studies of Gilead's sofosbuvir for hepatitis C

05-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has revealed positive top-line results from two Phase…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market

31-01-2013

Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

UK's NICE issues draft guideline for diagnosis and management of hepatitis B

17-01-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Study on generic HIV drugs prompts AHF to demand Gilead cuts ARV prices

16-01-2013

A new study published in the Annals of Internal Medicine that provides a snapshot of a simplified cost/benefit…

Anti-viralsAtriplaGenericsGilead SciencesNorth AmericaPharmaceuticalPricingStribild

MacroGenics in deal potentially worth $1 billion with Gilead for DART products

09-01-2013

Privately held US biotech firm MacroGenics has entered into a license agreement with Gilead Sciences…

BiotechnologyGilead SciencesLicensingMacroGenicsResearch

Gilead Sciences updates on hepatitis C development programs

07-01-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline…

Anti-viralsBiotechnologyGilead SciencesGS-5885Researchsofosbuvir

Gilead agrees to buy YM BioSciences for $510 million

13-12-2012

US biotech firm Gilead Sciences (Nasdaq: GILD) has agreed to acquire Canada's YM BioSciences (TSX: YM)…

BiotechnologyCYT387Gilead SciencesMergers & AcquisitionsOncologyPharmaceuticalYM Biosciences

Japan Tobacco files for Japanese approval of elvitegravir

11-12-2012

Japan Tobacco (TSE:2914) has filed a New Drug Application for marketing approval of a novel anti-HIV…

Anti-viralsAsia-PacificBiotechnologyelvitegravirGilead SciencesJapan TobaccoPharmaceuticalRegulationTorii Pharma

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Merck & Co and Gilead highlight new data at international HIV meeting

16-11-2012

US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

55 to 79 of 123 results

Back to top